Logo

Medtronic’s Affera Mapping and Ablation System Receives CE Mark for the Treatment of Atrial Arrhythmias

Share this
Medtronic

Medtronic’s Affera Mapping and Ablation System Receives CE Mark for the Treatment of Atrial Arrhythmias

Shots:

  • The company has received CE mark clearance for its Affera mapping & ablation system incl. the Sphere-9 catheter & Affera Prism-1 mapping software to treat atrial arrhythmias or fast, abnormal heart rhythms. The company plans to commercially launch the Affera system in the EU in H1’23 & is investigational in the US
  • The system integrates Sphere-9 pulsed-field ablation (PFA), radiofrequency, and high-density mapping. It maps and ablates atrial arrhythmias incl. AFib provides real-time feedback through its mapping and navigation software
  • The IDE pivotal trial (SPHERE Per-AF Trial) evaluates the safety & effectiveness of the Affera Mapping & Ablation System for treating persistent AF while the trial is currently in 12mos. follow up phase

Ref: Medtronic | Image: Medtronic

Related News:- Medtronic Reports (PULSED AF) Trial Results of PulseSelect PFA System for Atrial Fibrillation

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions